You are right, but in fact the initial paragraphs of the description of CD12 on clinicaltrials.gov does not mention SOC. It is virtually identical to the language in the article:
This was a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
This was from:
https://clinicaltrials.gov/study/NCT04347239?...amp;rank=2
What clearly happened was that there was that recent update to CD12, the posting of study results, and someone not too bright thought this a new study.
This was a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
This was from:
https://clinicaltrials.gov/study/NCT04347239?...amp;rank=2
What clearly happened was that there was that recent update to CD12, the posting of study results, and someone not too bright thought this a new study.
6
